**Plasma 9α,11β-PGF₂, a PGD₂ metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma**

G Bochenek, E Niżankowska, A Gielicz, M Świerczyńska, A Szczeklik


**Background:** Prostaglandin D₂ (PGD₂) is a major cyclooxygenase product generated by activated mast cells during an allergic response. Assessment of PGD₂ and its metabolites in patients with asthma has mostly been performed in urine, bronchoalveolar lavage fluid and induced sputum, whereas human plasma determinations have been performed only sporadically.

**Methods:** In 32 patients with allergic asthma and 50 healthy non-allergic controls, baseline plasma and urinary levels of 9α,11β-PGF₂, a primary PGD₂ metabolite, were assessed by gas chromatography/mass spectrometry. Serum tryptase levels were measured by fluoroenzyme immunoassay and urinary leukotriene E₄ (LTE₄) by ELISA. In a subgroup of 10 asthmatics (randomly selected from the 32 study patients) in whom bronchial allergen challenges with specific allergens (*Dermatophagoides pteronyssinus*, n = 4, mixed grass pollens, n = 6) were carried out, measurements were taken both before and after provocation.

**Results:** At baseline no significant differences between mean plasma and urinary levels of PGD₂ metabolite and serum tryptase levels were found in asthmatics or controls. Asthmatic patients had significantly higher urinary LTE₄ levels. Allergen challenge resulted in a significant early increase in the mean plasma 9α,11β-PGF₂ level and only a borderline but significant increase in the urinary 9α,11β-PGF₂ level within 2 hours after allergen challenge. The challenge did not produce statistically significant changes in serum tryptase levels. Urinary LTE₄ levels remained significantly increased 4 hours after allergen challenge.

**Conclusions:** PGD₂ is actively involved in the early asthmatic response to allergens. Measurement of 9α,11β-PGF₂ release into plasma rather than urine following allergen challenge is a sensitive marker of enhanced PGD₂ synthesis, most probably due to mast cell activation.

**METHODS**

**Subjects**

Two groups of subjects were studied. The first comprised 32 patients with allergic asthma who gave a history of dyspnoea after exposure to specific aeroallergens and had positive skin prick tests to them. They were in a stable condition and none had suffered an asthma exacerbation or respiratory tract infection within the preceding 6 weeks. Their clinical characteristics are shown in table 1.

Bronchial provocation tests with specific allergens (*Dermatophagoides pteronyssinus*, n = 4; mixed grass pollens, n = 6) were carried out in 10 subjects randomly selected from the group. The specific allergen used for the provocation was the one to which an individual gave an allergic history, had a positive skin test, and evidence of specific IgE antibodies in class >2. The subjects had mild asthma and had demonstrated bronchial hyperresponsiveness to histamine during the 2 weeks before the study. At the time, four were on inhaled corticosteroids (doses ≤400 µg budesonide). The

**Abbreviations:** EAR, early asthmatic response; FEV₁, forced expiratory volume in 1 second; LAR, late asthmatic response; LTE₄, leukotriene E₄; PGD₂, prostaglandin D₂
clinical characteristics of these 10 subjects are shown in table 2. The pollen challenges were performed out of season. The control group comprised 50 healthy non-allergic subjects with no history of asthma or allergy. Both skin prick tests to common aeroallergens and a qualitative in vitro assay for determination of specific IgE antibodies were negative (table 1).

Before entering the study each subject gave written informed consent and the protocol was approved by the local ethics committee.

Inhalation test with allergen

Allergen solutions (Aquagen SQ, ALK, Hørsholm, Denmark) were prepared from stock solutions (100 000 SQ-U/ml) of D pteronyssinus and mixed grass pollens by diluting in ALK diluent. A range of 10-fold incrementally increasing concentrations of the allergen from 1 SQ-U/ml to 100 000 SQ-U/ml were prepared immediately before the provocation. They were administered by abcPneumo 2000 RS (abcMED, Cracow, Poland) adjusted to controlled delivery of aerosolised substances during inhalation.

Forced expiratory volume in 1 second (FEV1) was measured before the challenge and subjects were excluded from further study if FEV1 was <80% of the predicted value. The provocation was commenced with the inhalation of 1 ml ALK diluent delivered during 10 quiet breaths. FEV1 was measured immediately after the completion of diluent inhalation and 5 and 10 minutes later. If FEV1 fell >15%, the test was terminated because of bronchial instability. Alternatively, the mean FEV1 was calculated from three measurements after diluent inhalation and regarded as the baseline value.

Inhalation of 1 ml of allergen extracts began with the lowest concentration (1 SQ-U/ml). FEV1 was recorded immediately, 5, and 10 minutes after termination of each inhalation of the incrementally increasing concentrations of allergen. The test was continued until the concentration of allergen provoking a fall of at least 20% in the mean post-diluent (baseline) FEV1 was reached (PC20). The challenge was concluded and EAR was recognised. When the highest allergen concentration (100 000 SQ-U/ml) was reached and no positive reaction occurred within 30 minutes, the test was regarded as negative. After completing the provocation test, FEV1 was measured every hour for the following 12 hours to record a possible LAR. This occurred if a second decrease in FEV1 of at least 15% was observed.

Bronchial provocation tests always started between 08.00 and 08.30 hours. Short acting antihistamines and cromones were withheld for at least 5 days before the test and long acting β2 agonists and theophylline were withheld for 24 hours. Short acting β2 agonists were not administered at least 8 hours before the challenge.

Blood collection

In all subjects blood samples were taken at baseline for measurement of 9α,11β-PGF2α and tryptase. In a subgroup of asthmatic subjects subjected to allergen challenge, blood samples were also collected at 5, 30, 60, 120 minutes after completion of the challenge (fall in FEV1 ≥20%).

For measurement of 9α,11β-PGF-2α, blood samples were immediately centrifuged at 3500 rpm for 10 minutes and 500 g deuterium labelled prostaglandin F2α ([2H4]PGF2α) as an internal standard was added to 1 ml plasma. For tryptase measurements blood samples were allowed to clot and serum was removed after centrifugation. Samples were immediately processed or stored at −80°C until assayed (up to 1 month).

Urine collection

Urine samples for 9α,11β-PGF2α and leukotriene E4 (LTE4) measurement were collected from all subjects at baseline (after a 2 hour accumulation of urine in the bladder (that is, 06.00–08.00 hours)). In addition, urine samples were also collected from 10 asthmatic subjects undergoing allergen challenge at 2 hour intervals (2, 4, 6, and 8 hours) after completion of the challenge.

Assessment of 9α,11β-PGF2α, tryptase, and LTE4

9α,11β-PGF2α was measured in plasma and urine by gas chromatography-negative ion chemical ionisation-mass spectrometry (GC-NICI-MS) following the extraction step using
RESULTS

Clinical observations

In all 10 asthmatics, inhalation of allergen triggered EAR manifested by dyspnoea and a fall in FEV₁ of ≥20% (from 20.8% to 50.4%; mean (SD) 31.1 (10.0)% between 5 and 10 minutes after completion of the challenge. The individual PC₂₀ values are shown in table 2. In five of the 10 patients EAR was followed by LAR within 6–8 hours of the challenge, characterised by a fall in FEV₁ of 16.0–24.5% (mean (SD) 19.6 (3.5)%) compared with baseline. All reactions were well controlled and therapeutically reversed.

Eicosanoids and tryptase baseline values

No significant differences were found between the mean baseline plasma and urinary levels of 9α,11β-PGF₂ measured in asthmatic subjects and controls (table 3). Patients with asthma had significantly higher urinary LTE₄ levels than controls (table 3). The baseline tryptase levels determined in asthmatics were similar to those in controls (table 3).

Plasma 9α,11β-PGF₂ following allergen challenge

Allergic reaction resulted in a significant early mean fivefold increase in plasma 9α,11β-PGF₂ levels (16.98 (5.62) pg/ml) compared with the mean baseline level (3.38 (0.34) pg/ml; mean difference 13.6 (95% CI 0.73 to 26.5), p<0.01, fig 1A). This value gradually declined but was still significantly higher when measured 30 minutes after the challenge (8.87 (2.37) pg/ml, mean difference 5.49 (95% CI 0.01 to 11.0), p<0.05). It tended to be higher 60 minutes after the challenge (5.99 (0.92) pg/ml, mean difference 2.61 (95% CI 0.53 to 4.7), p<0.05) and had returned to the baseline level by 120 minutes after the challenge (4.07 (0.59) pg/ml, mean difference 0.69 (95% CI −0.66 to 2.0), p>0.05).

The kinetics of the response were almost homogenous in all 10 asthmatics (fig 2A).

Serum tryptase following allergen challenge

Mean serum tryptase levels did not show significant changes when measured 5 minutes (5.11 (0.74) µg/l), 30 minutes (5.24 (0.77) µg/l), 60 minutes (5.33 (0.88) µg/l) and 120 minutes (5.05 (0.82) µg/l) after challenge compared with the mean baseline value (5.59 (0.71) µg/l, p>0.05), with mean differences of −0.48 (95% CI −1.47 to 0.5), −0.34 (95% CI −1.11 to 0.4), −0.25 (95% CI −1.36 to 0.9), and −0.54 (95% CI −1.73 to 0.6), respectively (fig 1A).

In individual subjects the values remained fairly stable, although inter-individual differences were observed (fig 2B).

Urinary 9α,11β-PGF₂ following allergen challenge

Allergic inhalation caused only a small but significant 1.5-fold increase in the mean urinary 9α,11β-PGF₂ level in samples collected during the first 2 hours after challenge (1.06 (0.14) ng/mg creatinine). Compared with baseline

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Mean (SE) baseline values of eicosanoids and tryptase in study groups</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Allergic asthma (n = 32)</td>
</tr>
<tr>
<td>Plasma 9α,11β-PGF₂ (pg/ml)</td>
<td>4.59 (2.5)</td>
</tr>
<tr>
<td>Serum tryptase (µg/l)</td>
<td>4.46 (1.84)</td>
</tr>
<tr>
<td>Urinary 9α,11β-PGF₂ (ng/mg creatinine)</td>
<td>0.92 (0.56)</td>
</tr>
<tr>
<td>Urinary LTE₄ (pg/mg creatinine)</td>
<td>538.4 (440.5)</td>
</tr>
</tbody>
</table>

*Difference between asthmatics and healthy controls.

Skin tests

Both the asthmatic and control subjects underwent skin prick tests with 12 common aeroallergens (Soluprick, ALK, Hørsholm, Denmark). The positive control was histamine hydrochloride (1 mg/ml) and the diluent for the allergens tested was used as a negative control. A positive skin prick test was defined as a mean wheal diameter of 3 mm larger than that of the negative control.

Measurements of specific IgE

In 10 asthmatics subjected to allergen challenge the concentrations of allergen specific antibodies were determined by a fluoroenzyme immunoassay method using the Pharmacia CAP system specific IgE FEIA (Pharmacia & Upjohn Diagnostics). Values of ≥0.35 kU/l represented positive results which were expressed in classes 0–6.

In all controls in vitro qualitative screening assay for allergen inhalation caused only a small but significant 1.5-fold increase in plasma 9α,11β-PGF₂ measured in asthmatic subjects and controls (table 3). The baseline tryptase levels determined in asthmatics were similar to those in controls (table 3). The baseline plasma and urinary levels of 9α,11β-PGF₂ were significantly higher when measured 30 minutes after the challenge (5.99 (0.92) pg/ml, mean difference 2.61 (95% CI 0.53 to 4.7), p<0.05) and had returned to the baseline level by 120 minutes after the challenge (4.07 (0.59) pg/ml, mean difference 0.69 (95% CI −0.66 to 2.0), p>0.05).

The kinetics of the response were almost homogenous in all 10 asthmatics (fig 2A).

Serum tryptase following allergen challenge

Mean serum tryptase levels did not show significant changes when measured 5 minutes (5.11 (0.74) µg/l), 30 minutes (5.24 (0.77) µg/l), 60 minutes (5.33 (0.88) µg/l) and 120 minutes (5.05 (0.82) µg/l) after challenge compared with the mean baseline value (5.59 (0.71) µg/l, p>0.05), with mean differences of −0.48 (95% CI −1.47 to 0.5), −0.34 (95% CI −1.11 to 0.4), −0.25 (95% CI −1.36 to 0.9), and −0.54 (95% CI −1.73 to 0.6), respectively (fig 1A).

In individual subjects the values remained fairly stable, although inter-individual differences were observed (fig 2B).

Urinary 9α,11β-PGF₂ following allergen challenge

Allergic inhalation caused only a small but significant 1.5-fold increase in the mean urinary 9α,11β-PGF₂ level in samples collected during the first 2 hours after challenge (1.06 (0.14) ng/mg creatinine). Compared with baseline

C18 Sep-Pak cartridge, derivatisation to pentafluorobenzyl ether (Hewlett Packard, Palo Alto, CA, USA). Deuterium labelled PGF₂α ([²H₄]PGF₂α) was used as an internal standard in a manner identical to gas chromatography-electron impact mass spectrometry as reported by Obata et al.³¹ Tryptase was measured in serum by a fluoroenzyme immunoassay method using UniCAP100 Tryptase System (Pharmacia & Upjohn, Uppsala, Sweden). LTE₄ excretion was analysed in non-purified urine samples by an enzyme linked immunosorbent assay (ELISA, Cayman Chemicals, Ann Arbor, MI, USA) according to the method of Kumlin et al.³⁴
levels (0.72 (0.1) ng/mg creatinine, mean difference 0.34 (95% CI −0.05 to 0.7)), the significance was of borderline significance ($p = 0.04$, fig 1C). The mean readings obtained from the remaining three 2 hour intervals (0.76 (0.09) ng/mg creatinine, mean difference 0.04 (95% CI 0.01 to 0.07)), respectively, were similar to the baseline value ($p > 0.05$, fig 1B).

There was considerable variability between individuals in the time courses (fig 2C). In five subjects with LAR the mean urinary 9α,11β-PGF₂α levels measured within 6–8 hours of the challenge did not vary significantly from the pre-challenge levels ($p > 0.05$).

**Urinary LTE₄ following allergen challenge**

The mean urinary LTE₄ level increased 2.5-fold over the baseline (397.8 (131.2) pg/mg creatinine) when measured in samples collected during the first 2 hours after completion of the challenge (956.4 (293.6) pg/mg creatinine, mean difference 558.6 (95% CI 100.8 to 1016.4), $p < 0.05$, fig 1B). It was still significantly higher in urine samples collected 2–4 hours (978.0 (259.9) pg/mg creatinine, mean difference 580.2 (95% CI 123.2 to 1037.2), $p < 0.05$) and 4–6 hours after completing

---

**Figure 1** Mean (SE) levels of (A) 9α,11β-PGF₂α (○) and tryptase (●) in blood and (B) 9α,11β-PGF₂α (■) and LTE₄ (▲) in urine before and after allergen provocation in 10 asthmatics. *$p < 0.05$, **$p < 0.01$.

**Figure 2** Individual excretion of (A) plasma 9α,11β-PGF₂α, (B) serum tryptase, (C) urinary 9α,11β-PGF₂α, and (D) urinary LTE₄ in samples collected from 10 asthmatics undergoing bronchial allergen challenge.
the challenge (607.7 (127.1) pg/mg creatinine, mean difference 209.9 (95% CI -4.27 to 424.1), p<0.05), but returned to the pre-challenge level within 6–8 hours (453.4 (97.3) pg/mg creatinine, mean difference 55.6 (95% CI -132.0 to 243.2), p>0.05).

The allergen challenge led to a rise in urinary LTE\textsubscript{4} excretion in all 10 asthmatics (fig 2D). Similar to urinary 9α,11β-PGF\textsubscript{2} levels, in the five subjects who developed LAR the mean urinary LTE\textsubscript{4} levels measured within 6–8 hours of the challenge were comparable to those measured at baseline (p>0.05).

**Analysis of correlations between the variables**

At baseline no correlation was found between plasma and urinary levels of 9α,11β-PGF\textsubscript{2} (r=0.35; p>0.05), between plasma 9α,11β-PGF\textsubscript{2} and serum tryptase levels (r=0.16; p>0.05), or between urinary LTE\textsubscript{4} and urinary 9α,11β-PGF\textsubscript{2} levels (r=0.23; p>0.05).

**DISCUSSION**

This study provides conclusive evidence that 9α,11β-PGF\textsubscript{2}, the primary metabolite of PGD\textsubscript{2}, increases significantly in plasma during EAR following an allergen challenge. All but one of the asthmatic subjects challenged with an allergen responded with an early fivefold increase in 9α,11β-PGF\textsubscript{2}. The increased values gradually returned to baseline within 2 hours of the challenge.

There are few data on plasma levels of PGD\textsubscript{2} and its metabolites in patients with bronchial asthma. In three children admitted to hospital with an acute asthmatic attack, plasma 9α,11β-PGF\textsubscript{2} levels were lower at the time of discharge than on admission.\textsuperscript{11} In another report two PGD\textsubscript{2} metabolites (9α,11β-PGF\textsubscript{2} and PGD-M) increased in the plasma of healthy volunteers after ingestion of niacin.\textsuperscript{11} Baseline plasma levels of both these metabolites were substantially increased in systemic mastocytosis.\textsuperscript{15} We have recently observed significantly higher baseline plasma levels of 9α,11β-PGF\textsubscript{2} in subjects with aspirin induced asthma than in asthmatics who tolerated aspirin.\textsuperscript{14} Furthermore, aspirin challenge led to a further significant rise in the metabolite in aspirin sensitive subjects.\textsuperscript{16}

In contrast to the plasma levels, only a small (1.5-fold) but significant rise was seen in the urinary 9α,11β-PGF\textsubscript{2} level in the first 2 hours following the allergen challenge. The mean values measured at the subsequent time intervals were comparable to the baseline level. In patients who developed LAR, no increase in the urinary 9α,11β-PGF\textsubscript{2} level occurred within 6–8 hours of the challenge. These findings are not fully in agreement with those of Sladek et al.\textsuperscript{10} who reported an early 3.8-fold rise in urinary levels of PGD-M, another PGD\textsubscript{2} metabolite, within 2 hours of inhalation of a threshold concentration of allergen in eight patients with atopic asthma. The measurement of PGD-M (9α,11β-dihydroxy-15-oxo-2,3,18,19-tetranorprostan-5-ene-1,2-dicarboxylic acid) rather than 9α,11β-PGF\textsubscript{2} may account for the difference. In five subjects with LAR there was no late rise in the urinary levels of this metabolite, in line with our own findings. O’Sullivan et al.\textsuperscript{16} showed that a single threshold dose of allergen inhaled by nine patients with allergic asthma precipitated bronchoconstriction followed by a distinct 3.5-fold increase in the urinary concentration of 9α,11β-PGF\textsubscript{2} in samples collected immediately after the reaction. In keeping with our results, they found no difference in baseline levels of this metabolite between asthmatics and healthy controls. In a study by O’Sullivan et al.\textsuperscript{16} a 2.8-fold increase in urinary levels of 9α,11β-PGF\textsubscript{2} was observed in 12 patients with mild atopic asthma not only during EAR but also during LAR. However, this late rise was smaller and more protracted. In this study two doses of allergen were inhaled 15 minutes apart. The discrepancies in the results might be due to different allergen challenge protocols, numbers of patients, or different assay methods. In the latter two studies\textsuperscript{10,16} the enzyme immuno-assay (EIA) method was used. This measures the sum of 9α,11β-PGF\textsubscript{2} and the two isomers of its dinor metabolite, whereas the GC-NICI-MS which we used is more specific and measures only 9α,11β-PGF\textsubscript{2}.\textsuperscript{19} At present the methods based on GC-MS are considered to be the gold standard for reliable routine quantification of eicosanoid formation in vivo in humans.\textsuperscript{20}

LTE\textsubscript{4} excretion into urine after allergen induced bronchoconstriction was more intense and protracted than the excretion of 9α,11β-PGF\textsubscript{2}. The concurrent appearance in the urine of the PGD\textsubscript{2} metabolite and LTE\textsubscript{4} may suggest mast cell activation during EAR, although it does not rule out participation of other cells. Since eosinophils, basophils, and macrophages also produce leukotrienes, this may explain why the excretion of LTE\textsubscript{4} was more abundant than that of 9α,11β-PGF\textsubscript{2} which almost entirely originates from mast cells. The role of cysteinyl leukotrienes in the bronchospastic reaction provoked by allergen was documented by Taylor et al.\textsuperscript{11} and confirmed by others.\textsuperscript{21,22} We did not find an increase in urinary LTE\textsubscript{4} levels during LAR, which is consistent with other reports.\textsuperscript{23}

In agreement with other investigators,\textsuperscript{21,22} we did not detect any changes in tryptase levels after allergen challenge. Tryptase is considered to be a marker of mast cell activation in systemic anaphylaxis and mastocytosis\textsuperscript{24} and increases in some subjects with aspirin induced asthma after oral aspirin challenge.\textsuperscript{25} A significant increase in mean serum tryptase levels was observed only after a positive oral aspirin challenge associated with extrapulmonary symptoms, but not after inhalation of lysine aspirin despite a comparable bronchoconstriction provoked by both challenges.\textsuperscript{26} Perhaps only massive mast cell degranulation leads to an increase in the serum tryptase concentration. An allergen precipitated rise in tryptase levels was reported in nasal lavage\textsuperscript{28} and bronchoalveolar lavage fluids\textsuperscript{29} of allergic subjects after local instillation of an allergen into the nose and bronchi, respectively.

In conclusion, this study shows for the first time that 9α,11β-PGF\textsubscript{2} measurements in plasma offer a sensitive way of measuring PGD\textsubscript{2} synthesis in the airways in a bronchoprovocation model of asthma. Its early appearance in the plasma immediately after the allergen provoked bronchospastic reaction corroborates the results of previous studies\textsuperscript{10,16} which show that PGD\textsubscript{2} is actively involved in EAR. This might in turn, though indirectly, point to mast cell activation. A small but significant increase in urinary levels of 9α,11β-PGF\textsubscript{2} may therefore give reasonable grounds to believe that measurement of this metabolite in urine is not as sensitive as in plasma.

**REFERENCES**

Neurodevelopmental defects after steroid treatment of premature lung disease


There has been much controversy in recent years regarding the early use of postnatal corticosteroids to treat preterm infants with respiratory distress syndrome (RDS). Short-term respiratory benefits must be weighed against the potential for detrimental neurodevelopmental effects.

This study reports follow-up data on growth, neurological and motor function, cognition, and school performance of two groups of ex-preterm infants assessed when reaching school age. In the original study, 262 preterm infants with severe RDS were randomly allocated to receive either early postnatal dexamethasone or placebo. The study had reported a significant reduction in chronic lung disease in the dexamethasone treated group without excess mortality. The children followed up at school age were the survivors of the original study. At school age (mean 8 years) children in the dexamethasone treated group were significantly shorter and had smaller head circumferences than the placebo treated controls. In addition, dexamethasone treated children had significantly poorer performance in most skill areas including motor coordination, visual motor integration, and IQ.

This follow up study supports the view that early postnatal corticosteroids cannot be recommended for the routine treatment of RDS or the prevention of chronic lung disease of prematurity.

K E Johnson
Paediatric Specialist Registrar, Darent Valley Hospital, Dartford, UK; donniebird@hotmail.com
Plasma 9\(\alpha,11\beta\)-PGF\(_2\), a PGD\(_2\) metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma

G Bochenek, E Nizankowska, A Gielicz, M Swierczynska and A Szczeklik

Thorax 2004 59: 459-464
doi: 10.1136/thx.2003.013573

Updated information and services can be found at:
http://thorax.bmj.com/content/59/6/459

These include:

References
This article cites 29 articles, 4 of which you can access for free at:
http://thorax.bmj.com/content/59/6/459#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Asthma (1782)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/